20374 Seneca Meadows Parkway
About Intrexon Corporation
Through the engineering of biology, Intrexon is helping to address some of the world’s most pressing challenges and is working with industry and government leaders to realize a better, healthier planet. Today our platform is delivering new therapies in health, supplying unique solutions to address global energy demand, developing unparalleled features and productivity advancements in food, creating innovative applications for consumers, and helping to restore and protect the environment.
To execute on its mission, Intrexon has integrated a suite of technologies and expertise across a number of cellular systems to drive development and commercialization of bio-based solutions. Our solutions include: Friendly™ Aedes mosquitoes genetically engineered to suppress the invasive Aedes aegypti mosquito; Arctic® apples that will not brown when bitten, sliced, or bruised; a clinically validated transcriptional gene switch to precisely control production of biotherapeutics; bovine reproductive technologies driving genetic gain for the dairy and beef industries; genetically engineered miniature swine models to provide better predictive efficacy in evaluation of new medicines; and our AquAdvantage® salmon bringing productivity benefits to the aquaculture industry through our majority-owned subsidiary AquaBounty. Intrexon’s cutting-edge platforms have broad applicability, thus opening the door to the considerable potential of engineered biology.
Intrexon and our collaborators are building solutions to challenging issues across fields as diverse as medicine, fuel, agriculture, nutrition, personal care, chemicals, and manufacturing, forging a sustainable path forward for current and future generations. We call our approach Better DNA® and invite you to discover more at www.dna.com or follow us on Twitter at @Intrexon, on Facebook and LinkedIn.
254 articles with Intrexon Corporation
1/3/2020Pharma, biotech and life sciences companies boost their leadership ranks with this weeks Movers & Shakers.
Intrexon To Achieve $175M Cash Goal, Appoints Helen Sabzevari, PhD, As New President And CEO And Will Change Name To Precigen To Reflect Healthcare Focus
Intrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, announced today that it will refocus the company on healthcare, change its name to Precigen, Inc. and, effective immediately, has appointed Helen Sabzevari, PhD, as President and CEO.
The company is changing its name to Precigen, Inc. and tapped Helen Sabzevari as its new president and chief executive officer.
Quarterly GAAP revenues of $23.0 million and net loss attributable to Intrexon of $53.6 million including non-cash charges of $19.5 million
Intrexon's subsidiary Precigen to host conference call to provide business and pipeline updates
Former head of IHS Markit Energy, Chemicals and Agribusiness Division to lead company for Intrexon's Methane Bioconversion Platform (MBP)
ActoBio Therapeutics™ Receives IND Green Light for New Antigen-Specific Immunotherapy Study Aimed at Improving Celiac Patients' Tolerance of Gluten
Celiac Disease is an underserved market with no approved pharmacological therapies
Quarterly GAAP revenues of $36.0 million and net loss attributable to Intrexon of $38.8 million including non-cash charges of $8.0 million
Intrexon Corporation announced it will release second quarter and first half 2019 financial results after the market closes on Thursday, August 8th, 2019.
Precigen Announces First Patient Dosed in Phase 1/1b Study of PRGN-3006 UltraCAR-T™ in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or Higher Risk Myelodysplastic Syndrome (MDS)
Milestone represents the first patient dosed with Precigen's transformative non-viral UltraCAR-T therapeutic platform that eliminates ex vivo expansion and reduces manufacturing time to fewer than two days following gene transfer
Intrexon Corporation and Surterra Wellness Partner in $100mm Deal to Advance Commercial Scale Fermentation-based Cannabinoid Production
Exclusive Global Agreement to Transform Surterra's Ability to Produce Specific Cannabinoids to Meet Growing Demand, Boost Innovation and Product Development
Intrexon Corporation and Precigen, Inc. announced their presentation at the JMP Securities Life Sciences Conference in New York.
Non-Browning Romaine lettuce demonstrates improved shelf life, reducing food waste and is not subject to regulation as a product produced through genetic engineering by the USDA
Intrexon Corporation announced the Company and its subsidiaries will participate in the 2019 BIO International Convention June 3-6th in Philadelphia.
Intrexon Corporation announced Randal J. Kirk, Chairman and Chief Executive Officer, will present at the Bank of America Merrill Lynch 2019 Healthcare Conference in Las Vegas on Wednesday, May 15th, at 3:40 p.m. Pacific Time.
Intrexon Corporation announced its first quarter financial results for 2019.
Intrexon Corporation and its majority owned Intrexon Health subsidiary Xogenex, announced that four abstracts will be presented as posters at the American Society of Gene and Cell Therapy Annual Meeting, which will be held April 29 - May 2, 2019, at the Washington Hilton in Washington, D.C.
Oxitec Signs New Multi-year Development Agreement to Apply 2nd Generation Technology to Control Soybean Looper
Oxitec to develop a safe, self-limiting insect capable of reducing pest populations and reversing insect resistance to biotech traits and chemistries
Intrexon to Highlight Microbial Cannabinoid Production Platform at the Paradigm Capital Biosynthesis Conference
Intrexon Corporation announced Thomas D. Reed, PhD, Founder and Chief Science Officer, will present at the Paradigm Capital Biosynthesis Conference on April 15, 2019 in Toronto.
Two therapeutic candidates from Precigen's game-changing UltraCAR-T™ therapeutic platform commencing clinical studies